BioStock: Pila Pharma’s CEO comments on the Q2 report

Malmö-based biotech company Pila Pharma advances towards clinical phase II studies with XEN-D0501 at a steady pace. During the second quarter of 2022 the company announced plans to enter a new indication with the drug candidate. BioStock asked the company’s CEO Dorte X. Gram about her views on the second quarter and about the plans ahead.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/08/pila-pharmas-ceo-comments-on-the-q2-report/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se